Subtitling task 2, Júlia Creus

Hello people! I want to talk to you about COVID-19 vaccine, ok? The one developed by the University of Oxford, together with AstraZeneca, which is a company, alright? Recently, they published the results for... so, the overall efficacy of the vaccine, and the number was seventy percent. Now, compared to the other two, with numbers in the reach of ninety-ninety five percent, this looks bad. However, it turns out that they made a mistake, with about three thousand people volunteers, and because they gave to these people a lower dose regime of the vaccine. So, basically, they gave the same amount of liquid, but there was less amount of vaccine in the liquid, it was diluted. So, this was a mistake, but it turns out, that when you do that in the first dose, and then you give the full amount on second, it looks like; the overall efficacy rises from seventy to around ninety percent. Now, taking in to acount, that this vaccine is cheaper than the other two, which is in the reach of two-three euros rather than twenty, whatever. And that it can be stored in fridges, alright? At fridge temperature, around eight degrees positive rather minus twenty minus eighty. So, of course, that all these two characteristics made this vaccine much better. So, the only problem would be the lower efficacy. But if it turns out that the overall efficacy is actually in the reach of ninety percent then that's really good. So, it looks like they are going to make new trials now, but then, of course, some people are saying "No, they are making new ones is because they did it alright the first time and so on". So, it's tricky.